Lipocine Inc. has announced the presentation of clinical data for LPCN 2401 at the ObesityWeek® annual meeting in Atlanta, Georgia, held from November 4 to 7, 2025. The results, featured in a poster session, include 20-week data from a completed Phase 2 trial evaluating LPCN 2401 in men with obesity. The study found that treatment with LPCN 2401, both alone and in combination with vitamin E, resulted in rapid improvements in body composition, including increased lean mass and reduced fat mass and fat-to-lean mass ratio, compared to placebo. Additionally, significant reductions in liver fat content and liver injury markers were observed after 12 weeks of treatment and maintained through 36 weeks. LPCN 2401 was reported to be well tolerated, with no concerning safety signals identified through 72 weeks of exposure. The clinical results were presented during the ObesityWeek® meeting.